Development of DNA-biochips for rational prescription of psychopharmaceuticals (Q11681): Difference between revisions
Jump to navigation
Jump to search
(Removed claim: financed by (P890): Directorate-General for Regional and Urban Policy (Q8361), Removing unnecessary financed by statement) |
(Changed label, description and/or aliases in fr: translated_label) |
||
| label / fr | label / fr | ||
Développement de biopuces à ADN pour la prescription rationnelle de psychopharmaceutiques | |||
Revision as of 09:18, 28 November 2021
Project Q11681 in Czech Republic
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Development of DNA-biochips for rational prescription of psychopharmaceuticals |
Project Q11681 in Czech Republic |
Statements
7,740,698.75 Czech koruna
0 references
11,073,961.0 Czech koruna
0 references
69.9 percent
0 references
31 October 2020
0 references
ESSENCE LINE, s.r.o.
0 references
50°4'11.50"N, 14°22'51.56"E
0 references
50°4'6.46"N, 14°23'8.41"E
0 references
15000
0 references
15000
0 references
Cílem projektu je vyvinout nový DNA-biochip pro racionalizovanou preskripci psychofarmak pro pacienty s psychiatrickým onemocněním a tím přinést prospěch nejen pacientovi, ale snížit náklady zdravotních pojišťoven. Přínosem projektu bude bezpečnější a efektivnější preskripce psychofarmak, což povede k úspěšnější farmakoterapii, zvýší komfort pacienta v podobě pozitivní terapie a sníží náklady na neefektivně aplikovaná psychofarmaka a negativní dopady na pacienta. a. (Czech)
0 references
The aim of the project is to develop a new DNA-biochip for rationalised prescription of psychopharmaceuticals for patients with psychiatric diseases and thus bring benefits not only to the patient, but to reduce the costs of health insurance companies. The benefit of the project will be safer and more effective prescription of psychopharmaceuticals, which will lead to more successful pharmacotherapy, increase patient comfort in the form of positive therapy and reduce the cost of inefficiently applied psychopharmaceuticals and negative effects on the patient. a. (English)
22 October 2020
0 references
Identifiers
CZ.01.1.02/0.0/0.0/17_107/0012433
0 references